Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
P-CAB PPI in the eradication of : a systematic review and network meta-analysis.
Jiang Y, Zhang R, Fang Y, Zhao R, Fu Y, Ren P Therap Adv Gastroenterol. 2024; 17:17562848241241223.
PMID: 38751605 PMC: 11095192. DOI: 10.1177/17562848241241223.
References
1.
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M
. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016; 65(9):1439-46.
PMC: 5036253.
DOI: 10.1136/gutjnl-2015-311304.
View
2.
Jung Y, Kim S, Kim H, Noh S, Park J, Sohn C
. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of : A Real-World Evidence Study. Gut Liver. 2022; 17(5):711-721.
PMC: 10502490.
DOI: 10.5009/gnl220218.
View
3.
Graham D, Lu H, Yamaoka Y
. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007; 12(4):275-8.
DOI: 10.1111/j.1523-5378.2007.00518.x.
View
4.
Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A
. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014; 106(1):81-7.
DOI: 10.1016/j.diabres.2014.07.009.
View
5.
Choi Y, Lee Y, Kim J, Kim J, Moon J, Lim Y
. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. Gut Liver. 2022; 16(4):535-546.
PMC: 9289827.
DOI: 10.5009/gnl220055.
View